Home-Based Hypertension Care South Africa
Ozempic and Cardiovascular Risk: New Findings Demand Closer Scrutiny
Table of Contents
What Happened? A Closer Look at the SELECT Trial
A major clinical trial, the SELECT trial, has revealed a potential increased risk of serious cardiovascular events – including heart attack, stroke, and cardiovascular death – in individuals with obesity and established cardiovascular disease who were treated with semaglutide (Ozempic) compared to those receiving a placebo. The trial involved over 17,600 participants across 30 countries and followed them for an average of 3.4 years. While semaglutide demonstrated significant weight loss, this benefit was accompanied by a concerning signal regarding cardiovascular safety.
The Data: Key Findings from the SELECT Trial
The study found that 6.5% of participants taking semaglutide experienced a major adverse cardiovascular event (MACE) compared to 4.9% in the placebo group. this translates to a hazard ratio of 1.33, indicating a 33% increased risk.Though, it’s crucial to note that the trial also showed a significant reduction in the development of type 2 diabetes among participants.
| Outcome | Semaglutide Group (%) | Placebo Group (%) | Hazard Ratio |
|---|---|---|---|
| MACE (Heart Attack, Stroke, Cardiovascular Death) | 6.5 | 4.9 | 1.33 |
| New-Onset Type 2 Diabetes | 15.0 | 25.3 | 0.57 |
Who is Affected? Understanding the Patient Population
The SELECT trial specifically enrolled individuals with a body mass index (BMI) of 27 or higher *and* established cardiovascular disease, such as a history of heart attack, stroke, or peripheral artery disease. This is a critical distinction. The findings do *not* necessarily apply to individuals using semaglutide for weight loss who do not have pre-existing heart conditions. however, the results raise questions about the potential for increased risk even in those with less severe cardiovascular risk factors.
It’s critically important to emphasize that the trial participants were already at higher risk due to thier existing conditions.The study doesn’t prove that semaglutide *caused* the increased cardiovascular events, only that there was an association.
Why Does This Matter? The Implications for Prescribing practices
The SELECT trial results are a wake-up call. For months, semaglutide and similar drugs have been lauded as miracle weight-loss solutions.This trial demonstrates that benefits must always be weighed against potential risks, especially in vulnerable populations.Clinicians need to carefully assess the cardiovascular health of patients before prescribing semaglutide and closely monitor them for any signs of heart problems during treatment.
Timeline of Events & Key Developments
- August 2023: Results of the SELECT trial are presented at the European Society of cardiology Congress and simultaneously published.